Induction of Neutrophilic Traps ( NETs ) by the Environment and Infectious Inflammatory Lung Cystic Fibrosis

Secretion Induction of Neutrophil Extracellular Traps (NETs)in Inflammatory and Infectious Environment of Mucoviscidose

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02564393

Acronym

MucoNETs

Enrollment

Registered

2015-09-30

Start date

2011-05-31

Completion date

Unknown

Last updated

2015-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Brief summary

The study is defined in 3 stages of in vitro assays : Phase 1 : Secretion of NETs in response to lung disease and their secretion of factors. This is a transversal study in which we compare : * Producing NETs (DNA and proteases ) by neutrophils purified from sputum and blood of patients * Producing NETs (DNA and proteases ) by purified neutrophils in the blood of patients and blood of control subjects Phase 2: Mechanisms of activation of NETs secretory pathways . This phase will identify receptors (TLR ) involved in the secretion of NETs and analyze the involvement of dependent transduction pathways calcium and PKC . It will be performed on control blood neutrophils. Phase 3: Analysis of cell death ( NETose ) This is a transversal study that will analyze : the mode of cell death of neutrophils purified blood and sputum of patients and control blood neutrophils by flow cytometry and transmission electron microscopy .

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Patients : * Men or women over 18 * Patients with mucoviscidose in stable condition, i.e. not having presented an acute push of bronchopulmonary attack requiring a antibiothérapie or a hospitalization for treatment of its disease during the 2 previous weeks * Signed consent Volunteers : * Men or women over 18 * Without respiratory antecedent nor known respiratory pathology * Signed consent

Exclusion criteria

Patients : * In exclusion period of an other study Volunteers : * In exclusion period of an other study * Antibiotic treatment and/or anti-inflammatory drug (AINS or corticoids) in the 2 weeks before inclusion in the study

Design outcomes

Primary

Measure	Time frame
the DNA concentration secreted into the extracellular environment neutrophil activated	1 hour

Countries

France

Outcome results